Stock Events

Stock Events

Nicox SA 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

23OctExpected
Q3 2025
-0.12
0.21
0.54
0.88
Expected EPS
N/A
Actual EPS
-0.121690136568

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NXOA.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, Inc. competes in the ophthalmology space with treatments for eye diseases, directly competing with Nicox's focus on eye health.
Novartis
NVS
Mkt Cap297.32B
Novartis AG, through its Alcon eye care division, offers products that compete in the same market as Nicox's eye health solutions.
Bausch Health Companies
BHC
Mkt Cap1.99B
Bausch Health Companies Inc., formerly Valeant Pharmaceuticals, has a significant presence in the eye health market, making it a direct competitor to Nicox.
Opko Health
OPK
Mkt Cap875.18M
OPKO Health, Inc. has a diversified portfolio that includes ophthalmology, competing with Nicox in the eye health sector.
EyePoint
EYPT
Mkt Cap1.12B
EyePoint Pharmaceuticals, Inc. focuses on developing treatments for eye diseases, directly competing with Nicox's product offerings.
Alcon
ALC
Mkt Cap37.27B
Alcon Inc. specializes in eye care products across surgery, vision care, and ophthalmology, competing with Nicox in the broader eye health market.
Regenxbio
RGNX
Mkt Cap440.26M
REGENXBIO Inc. is involved in the development of gene therapies for eye diseases, offering innovative treatments that compete with Nicox's solutions.
Staar Surgical
STAA
Mkt Cap1B
STAAR Surgical Company specializes in implantable lenses and other products for the eye, competing with Nicox in the surgical eye care market.

About

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve eye health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, a NO-donating phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Biot, France.
Show more...
CEO
Dr. Gavin M. Spencer
Employees
5
Country
United Kingdom
ISIN
FR0013018124

Listings

STU
DE
NXOA.STU
MU
DE
NXOA.MU
LSE
GB
0RCQ.LSE
F
DE
NXOA.F

0 Comments

Share your thoughts

FAQ

What is Nicox SA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nicox SA stocks are traded under the ticker NXOA.MU.
When is the next Nicox SA earnings date?▼
Nicox SA is going to release the next earnings report on September 02, 2026.
What were Nicox SA earnings last quarter?▼
NXOA.MU earnings for the last quarter are -0.12 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Nicox SA have?▼
As of April 12, 2026, the company has 5 employees.
In which sector is Nicox SA located?▼
Nicox SA operates in the Energy sector.
When did Nicox SA complete a stock split?▼
Nicox SA has not had any recent stock splits.
Where is Nicox SA headquartered?▼
Nicox SA is headquartered in Biot, United Kingdom.